• Oct 5, 2026

  $252.93-1.21%

  J&J closed down 1.21%, while comparable pharmaceutical companies moved -0.79% on average, with 3 of 6 falling and 3 rising [1]. The decline was a little steeper than the group's, and the peers diverged widely, from ABT +2.67% to BMY -3.83% [1]. Volume was 1.5x the trailing 20-session average [2].

  • 1Peer group
  • 2Market data

• Oct 2, 2026

  $256.03-1.02%

• Oct 1, 2026

  $258.66-2.30%

  Comparable pharmaceutical companies fell 1.49% on average, with all 6 of 6 declining [1]. Johnson & Johnson's 2.30% drop was steeper than the group average, so it fell alongside its peers but by more [1]. The other items were opinion and comparison pieces that reported no company event.

  • 1Peer group

• Sep 30, 2026

  $264.74-1.06%

  Johnson & Johnson fell 1.06% on a day when comparable pharmaceutical companies moved -1.53% on average, with all 6 of 6 falling [1]. The company's decline was smaller than the cohort average.

  • 1Peer group

• Sep 29, 2026

  $267.57-1.61%

  Johnson & Johnson fell 1.61% on a day when comparable Pharmaceutical Preparations companies moved only -0.16% on average, with 4 of 6 falling and 1 rising [1]. The decline was therefore much larger than the peer group's and was not shared by it [1].

  • 1Peer group

• Sep 28, 2026

  $271.95+0.27%

• Sep 25, 2026

  $271.22+0.20%

Closing prices for JNJ. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.